Statins, diabetes, obesity, nonalcoholic fatty liver disease, and hepatocellular carcinoma

被引：0

作者：

Jun Han ^{[1
]}

Wen-Tao Yan ^{[1
,2
]}

Bing Quan ^{[1
,2
]}

Ming-Da Wang ^{[1
]}

Tian Yang ^{[1
]}

机构：

[1] Department of Hepatic Surgery, Eastern Hepatobiliary Surgery Hospital, the Second Military Medical University

[2] Department of Clinical Medicine, the Second Military Medical University

来源：

Hepatobiliary & Pancreatic Diseases International | 2019年 / 18卷 / 02期

关键词：

HCC; Statins; and hepatocellular carcinoma; diabetes; nonalcoholic fatty liver disease; obesity;

D O I：

暂无

中图分类号：

R735.7 [肝肿瘤]; R587.1 [糖尿病]; R575 [肝及胆疾病];

学科分类号：

1002 ; 100201 ; 100214 ;

摘要：

To the Editor:We read with great interest the recent article by Chang et al.[1].By analyzing the data of 1350 cirrhotic patients,the authors concluded that statin significantly decreases the risk of decompensation of cirrhosis,mortality and hepatocellular carcinoma

引用

页码：202 / 202

页数：1

共 50 条

[41] Clinicopathological features of hepatocellular carcinoma in patients with nonalcoholic fatty liver disease
Yoshihiro Mikuriya
Hirotaka Tashiro
Tsuyoshi Kobayashi
Shintaro Kuroda
Tomoyuki Abe
Masakazu Hashimoto
Hideki Ohdan
[J]. Langenbeck's Archives of Surgery, 2015, 400 : 471 - 476
[42] Nonalcoholic fatty liver disease (NAFLD) and hepatocellular carcinoma: How common?
Mittal S.
White D.L.
Kanwal F.
Sussman N.
El-Serag H.B.
[J]. Current Hepatology Reports, 2015, 14 (2) : 87 - 98
[43] The clinical picture of nonalcoholic fatty liver disease From obesity to carcinoma
Roeb, Elke
[J]. GASTROENTEROLOGE, 2020, 15 (02): : 78 - 87
[44] Antidiabetic Drugs and Statins in Nonalcoholic Fatty Liver Disease
Kothari, Sneha
Dhami-Shah, Hiteshi
Shah, Samir R.
[J]. JOURNAL OF CLINICAL AND EXPERIMENTAL HEPATOLOGY, 2019, 9 (06) : 723 - 730
[45] Main Risk Factors of Type 2 Diabetes Mellitus with Nonalcoholic Fatty Liver Disease and Hepatocellular Carcinoma
Qi, Yueying
Fan, Lirong
Ran, Decong
Xu, Jieda
Wang, Yuansong
Wu, Jin
Zhang, Zhongyong
[J]. JOURNAL OF ONCOLOGY, 2021, 2021
[46] Diabetes Is Associated With Increased Risk of Hepatocellular Carcinoma in Patients With Cirrhosis From Nonalcoholic Fatty Liver Disease
Yang, Ju Dong
Ahmed, Fowsiyo
Mara, Kristin C.
Addissie, Benyam D.
Allen, Alina M.
Gores, Gregory J.
Roberts, Lewis R.
[J]. HEPATOLOGY, 2020, 71 (03) : 907 - 916
[47] Statins and nonalcoholic fatty liver disease: a bright future?
Athyros, Vasilios G.
Katsiki, Niki
Karagiannis, Asterios
Mikhailidis, Dimitri P.
[J]. EXPERT OPINION ON INVESTIGATIONAL DRUGS, 2013, 22 (09) : 1089 - 1093
[48] The Role of Statins in the Management of Nonalcoholic Fatty Liver Disease
Doumas, Michael
Imprialos, Konstantinos
Dimakopoulou, Aikaterini
Stavropoulos, Konstantinos
Binas, Athanasios
Athyros, Vasilios G.
[J]. CURRENT PHARMACEUTICAL DESIGN, 2018, 24 (38) : 4587 - 4592
[49] Diabetes and Nonalcoholic Fatty Liver Disease
Kantartzis, Konstantinos
Gastaldelli, Amalia
Magkos, Faidon
Lavoie, Jean-Marc
[J]. EXPERIMENTAL DIABETES RESEARCH, 2012,
[50] Nonalcoholic fatty liver disease and diabetes
Bellini, Maria Irene
Urciuoli, Irene
Del Gaudio, Giovanni
Polti, Giorgia
Iannetti, Giovanni
Gangitano, Elena
Lori, Eleonora
Lubrano, Carla
Cantisani, Vito
Sorrenti, Salvatore
D'Andrea, Vito
[J]. WORLD JOURNAL OF DIABETES, 2022, 13 (09) : 668 - 682

← 1 2 3 4 5 →